Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study)

Background: Atazanavir without ritonavir, despite efficacy and tolerability, shows low plasma concentrations that warrant optimization. Methods: In a randomized, controlled, pilot trial, stable HIV-positive patients on atazanavir/ritonavir (with tenofovir/emtricitabine) were switched to atazanavir. In the standard-dose arm, atazanavir was administered as 400 mg once daily, while according to patients’ genetics (PXR, ABCB1 and SLCO1B1), in the pharmacogenetic arm: patients with unfavourable genotypes received 200 mg of atazanavir twice daily. EudraCT number: 2009-014216-35. Results: Eighty patients were enrolled with balanced baseline characteristics. The average atazanavir exposure was 253 ng/mL (150–542) in the pharmacogenetic arm versus 111 ng/mL (64–190) in the standard-dose arm (P,0.001); 28 patients in the pharmacogenetic arm (75.7%) had atazanavir exposure .150 ng/mL versus 14 patients (38.9%) in the standard-dose arm (P¼0.001). Immunovirological and laboratory parameters had a favourable outcome throughout the study with non-significant differences between study arms. Conclusions: Atazanavir plasma exposure is higher when the schedule is chosen according to the patient’s genetic profile.